Skip to main content

Advertisement

SpringerLink
Log in

Microenvironment of the Involuting Mammary Gland Mediates Mammary Cancer Progression

  • Published:
Journal of Mammary Gland Biology and Neoplasia Aims and scope Submit manuscript

Abstract

Breast cancer diagnosed after a completed pregnancy has higher metastatic potential and therefore a much poorer prognosis. We hypothesize that following pregnancy the process of mammary gland involution, which returns the gland to its pre-pregnant state, co-opts some of the programs of wound healing. The pro-inflammatory milieu that results, while physiologically normal, promotes tumor progression. In this review, the similarities between mammary gland involution after cessation of milk-production and pathological tissue remodeling are discussed in light of emerging data demonstrating a role for pathological tissue remodeling in cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

Abbreviations

ECM:

extracellular matrix

TGFβ:

transforming growth factor beta

FN:

fibronectin

LN1:

laminin 1

LN5:

laminin 5

MMP:

matrix metalloproteinase

CTGF:

connective tissue growth factor

SD:

Sprague–Dawley

References

  1. MacMahon B, Cole P, Brown J. Etiology of human breast cancer: a review. J Natl Cancer Inst 1973;50(1):21–42.

    PubMed  CAS  Google Scholar 

  2. Rosner B, Colditz GA, Willett WC. Reproductive risk factors in a prospective study of breast cancer: the nurses’ health study. Am J Epidemiol 1994;139(8):819–35.

    PubMed  CAS  Google Scholar 

  3. Pike MC, Krailo MD, Henderson BE, Casagrande JT, Hoel DG. ‘Hormonal’ risk factors, ‘breast tissue age’ and the age-incidence of breast cancer. Nature 1983;303(5920):767–70.

    PubMed  CAS  Google Scholar 

  4. Albrektsen G, Heuch I, Tretli S, Kvale G. Breast cancer incidence before age 55 in relation to parity and age at first and last births: a prospective study of one million Norwegian women. Epidemiology 1994;5(6):604–11.

    PubMed  CAS  Google Scholar 

  5. Bladstrom A, Anderson H, Olsson H. Worse survival in breast cancer among women with recent childbirth: results from a Swedish population-based register study. Clin Breast Cancer 2003;4(4):280–5.

    Article  PubMed  Google Scholar 

  6. Whiteman MK, Hillis SD, Curtis KM, McDonald JA, Wingo PA, Marchbanks PA. Reproductive history and mortality after breast cancer diagnosis. Obstet Gynecol 2004;104 1:146–54.

    PubMed  Google Scholar 

  7. Albrektsen G, Heuch I, Kvale G. Further evidence of a dual effect of a completed pregnancy on breast cancer risk. Cancer Causes Control 1996;7(4):487–8.

    PubMed  CAS  Google Scholar 

  8. Daling JR, Malone KE, Doody DR, Anderson BO, Porter PL. The relation of reproductive factors to mortality from breast cancer. Cancer Epidemiol Biomark Prev 2002;11(3):235–41.

    Google Scholar 

  9. Kroman N, Mouridsen HT. Prognostic influence of pregnancy before, around, and after diagnosis of breast cancer. Breast 2003;12(6):516–21.

    PubMed  Google Scholar 

  10. Mueller MM, Fusenig NE. Friends or foes—bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 2004;4(11):839–49.

    PubMed  CAS  Google Scholar 

  11. Schedin P, Elias A. Multistep tumorigenesis and the microenvironment. Breast Cancer Res 2004;6(2):93–101.

    PubMed  CAS  Google Scholar 

  12. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420(6917):860–7.

    PubMed  CAS  Google Scholar 

  13. Bissell MJ, Radisky D. Putting tumours in context. Nat Rev Cancer 2001;1(1):46–54.

    PubMed  CAS  Google Scholar 

  14. Tlsty TD. Stromal cells can contribute oncogenic signals. Semin Cancer Biol 2001;11(2):97–104.

    PubMed  CAS  Google Scholar 

  15. Park CC, Bissell MJ, Barcellos-Hoff MH. The influence of the microenvironment on the malignant phenotype. Mol Med Today 2000;6(8):324–9.

    PubMed  CAS  Google Scholar 

  16. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 2006;6(5):392–401.

    PubMed  CAS  Google Scholar 

  17. Desmouliere A, Guyot C, Gabbiani G. The stroma reaction myofibroblast: a key player in the control of tumor cell behavior. Int J Dev Biol 2004;48(5–6):509–17.

    PubMed  CAS  Google Scholar 

  18. Orimo A, Weinberg RA. Stromal fibroblasts in cancer: a novel tumor-promoting cell type. Cell Cycle 2006;5(15):1597–601.

    PubMed  CAS  Google Scholar 

  19. Gabbiani G. The myofibroblast in wound healing and fibrocontractive diseases. J Pathol 2003;200(4):500–3.

    PubMed  CAS  Google Scholar 

  20. De Marzo AM, DeWeese TL, Platz EA, Meeker AK, Nakayama M, Epstein JI, et al. Pathological and molecular mechanisms of prostate carcinogenesis: implications for diagnosis, detection, prevention, and treatment. J Cell Biochem 2004;91(3):459–77.

    PubMed  Google Scholar 

  21. Shishodia S, Aggarwal BB. Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates activation of cigarette smoke-induced nuclear factor (NF)-kappaB by suppressing activation of IkappaBalpha kinase in human non-small cell lung carcinoma: correlation with suppression of cyclin D1, COX-2, and matrix metalloproteinase-9. Cancer Res 2004;64(14):5004–12.

    PubMed  CAS  Google Scholar 

  22. Barcellos-Hoff MH, Ravani SA. Irradiated mammary gland stroma promotes the expression of tumorigenic potential by unirradiated epithelial cells. Cancer Res 2000;60(5):1254–60.

    PubMed  CAS  Google Scholar 

  23. Martins-Green M, Boudreau N, Bissell MJ. Inflammation is responsible for the development of wound-induced tumors in chickens infected with Rous sarcoma virus. Cancer Res 1994;54(16):4334–41.

    PubMed  CAS  Google Scholar 

  24. Kuperwasser C, Chavarria T, Wu M, Magrane G, Gray, JW, Carey L, et al. Reconstruction of functionally normal and malignant human breast tissues in mice. Proc Natl Acad Sci U S A 2004;101(14):4966–71.

    PubMed  CAS  Google Scholar 

  25. Chang HY, Nuyten DS, Sneddon JB, Hastie T, Tibshirani R, Sorlie T, et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci U S A 2005;102(10):3738–43.

    PubMed  CAS  Google Scholar 

  26. Nuyten DS, Kreike B, Hart AA, Chi JT, Sneddon JB, Wessels LF, et al. Predicting a local recurrence after breast-conserving therapy by gene expression profiling. Breast Cancer Res 2006;8(5):R62.

    PubMed  Google Scholar 

  27. Strange R, Li F, Saurer S, Burkhardt A, Friis RR. Apoptotic cell death and tissue remodelling during mouse mammary gland involution. Development 1992;115(1):49–58.

    PubMed  CAS  Google Scholar 

  28. Masso-Welch PA, Darcy KM, Stangle-Castor NC, Ip MM. A developmental atlas of rat mammary gland histology. J Mammary Gland Biol Neoplasia 2000;5(2):165–85.

    PubMed  CAS  Google Scholar 

  29. Lund LR, Romer J, Thomasset N, Solberg H, Pyke C, Bissell MJ, et al. Two distinct phases of apoptosis in mammary gland involution: proteinase-independent and -dependent pathways. Development 1996;122(1):181–93.

    PubMed  CAS  Google Scholar 

  30. Schedin PJ, Thackray LB, Malone P, Fontaine SC, Friis RR, Strange R. Programmed cell death and mammary neoplasia. Cancer Treat Res 1996;83:3–22.

    PubMed  CAS  Google Scholar 

  31. Dickson SR, Warburton MJ. Enhanced synthesis of gelatinase and stromelysin by myoepithelial cells during involution of the rat mammary gland. J Histochem Cytochem 1992;40(5):697–703.

    PubMed  CAS  Google Scholar 

  32. Wyllie AH, Kerr JF, Currie AR. Cell death: the significance of apoptosis. Int Rev Cytol 1980;68:251–306.

    Article  PubMed  CAS  Google Scholar 

  33. Monks J, Geske FJ, Lehman L, Fadok VA. Do inflammatory cells participate in mammary gland involution? J Mammary Gland Biol Neoplasia 2002;7(2):163–76.

    PubMed  Google Scholar 

  34. Monaghan P, Warburton MJ, Perusinghe N, Rudland PS. Topographical arrangement of basement membrane proteins in lactating rat mammary gland: comparison of the distribution of type IV collagen, laminin, fibronectin, and Thy-1 at the ultrastructural level. Proc Natl Acad Sci U S A 1983;80(11):3344–8.

    PubMed  CAS  Google Scholar 

  35. Talhouk RS, Bissell MJ, Werb Z. Coordinated expression of extracellular matrix-degrading proteinases and their inhibitors regulates mammary epithelial function during involution. J Cell Biol 1992;118(5):1271–82.

    PubMed  CAS  Google Scholar 

  36. Alexander CM, Howard EW, Bissell MJ, Werb Z. Rescue of mammary epithelial cell apoptosis and entactin degradation by a tissue inhibitor of metalloproteinases-1 transgene. J Cell Biol 1996;135(6 Pt 1):1669–77.

    PubMed  CAS  Google Scholar 

  37. Giannelli G, Pozzi A, Stetler-Stevenson WG, Gardner HA, Quaranta V. Expression of matrix metalloprotease-2-cleaved laminin-5 in breast remodeling stimulated by sex steroids. Am J Pathol 1999;154(4):1193–201.

    PubMed  CAS  Google Scholar 

  38. Meredith JE, Jr., Fazeli B, Schwartz MA. The extracellular matrix as a cell survival factor. Mol Biol Cell 1993;4(9):953–61.

    PubMed  CAS  Google Scholar 

  39. Coucouvanis E, Martin GR. Signals for death and survival: a two-step mechanism for cavitation in the vertebrate embryo. Cell 1995;83(2):279–87.

    PubMed  CAS  Google Scholar 

  40. Boudreau N, Sympson CJ, Werb Z, Bissell MJ. Suppression of ICE and apoptosis in mammary epithelial cells by extracellular matrix. Science 1995;267(5199):891–3.

    PubMed  CAS  Google Scholar 

  41. Humphreys RC, Krajewska M, Krnacik S, Jaeger R, Weiher H, Krajewski S, et al. Apoptosis in the terminal endbud of the murine mammary gland: a mechanism of ductal morphogenesis. Development 1996;122(12):4013–22.

    PubMed  CAS  Google Scholar 

  42. Streuli CH, Gilmore AP. Adhesion-mediated signaling in the regulation of mammary epithelial cell survival. J Mammary Gland Biol Neoplasia 1999;4(2):183–91.

    PubMed  CAS  Google Scholar 

  43. Schedin P, Strange R, Mitrenga T, Wolfe P, Kaeck M. Fibronectin fragments induce MMP activity in mouse mammary epithelial cells: evidence for a role in mammary tissue remodeling. J Cell Sci 2000;113(Pt 5):795–806.

    PubMed  CAS  Google Scholar 

  44. Debnath J, Mills KR, Collins NL, Reginato MJ, Muthuswamy SK, Brugge JS. The role of apoptosis in creating and maintaining luminal space within normal and oncogene-expressing mammary acini. Cell 2002;111(1):29–40.

    PubMed  CAS  Google Scholar 

  45. Talhouk RS, Chin JR, Unemori EN, Werb Z, Bissell MJ. Proteinases of the mammary gland: developmental regulation in vivo and vectorial secretion in culture. Development 1991;112(2):439–49.

    PubMed  CAS  Google Scholar 

  46. Schedin P, Mitrenga T, McDaniel S, Kaeck M. Mammary ECM composition and function are altered by reproductive state. Mol Carcinog 2004;41(4):207–20.

    PubMed  CAS  Google Scholar 

  47. Parks WC, Wilson CL, Lopez-Boado YS. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol 2004;4(8):617–29.

    PubMed  CAS  Google Scholar 

  48. Stamenkovic I. Extracellular matrix remodelling: the role of matrix metalloproteinases. J Pathol 2003;200 4:448–64.

    PubMed  CAS  Google Scholar 

  49. Alexander CM, Selvarajan S, Mudgett J, Werb Z. Stromelysin-1 regulates adipogenesis during mammary gland involution. J Cell Biol 2001;152(4):693–703.

    PubMed  CAS  Google Scholar 

  50. Clarkson RW, Wayland MT, Lee J, Freeman T, Watson CJ. Gene expression profiling of mammary gland development reveals putative roles for death receptors and immune mediators in post-lactational regression. Breast Cancer Res 2004;6(2):R92–109.

    PubMed  CAS  Google Scholar 

  51. Stein T, Morris JS, Davies CR, Weber-Hall SJ, Duffy MA, Heath VJ, et al. Involution of the mouse mammary gland is associated with an immune cascade and an acute-phase response, involving LBP, CD14 and STAT3. Breast Cancer Res 2004;6(2):R75–91.

    PubMed  CAS  Google Scholar 

  52. D’Cruz CM, Moody SE, Master SR, et al. Persistent parity-induced changes in growth factors, TGF-beta3, and differentiation in the rodent mammary gland. Mol Endocrinol 2002;16(9):2034–51.

    PubMed  CAS  Google Scholar 

  53. Egeblad M, Littlepage LE, Werb Z. The fibroblastic coconspirator in cancer progression. Cold Spring Harbor Symp Quant Biol 2005;70:383–8.

    PubMed  CAS  Google Scholar 

  54. Bissell MJ, Labarge MA. Context, tissue plasticity, and cancer: are tumor stem cells also regulated by the microenvironment? Cancer Cell 2005;7(1):17–23.

    PubMed  CAS  Google Scholar 

  55. de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006;6(1):24–37.

    PubMed  Google Scholar 

  56. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004;4(1):71–8.

    PubMed  CAS  Google Scholar 

  57. Wyckoff J, Wang W, Lin EY, Wang Y, Pixley F, Stanley ER, et al. A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors. Cancer Res 2004;64(19):7022–9.

    PubMed  CAS  Google Scholar 

  58. Lin EY, Nguyen AV, Russell RG, Pollard JW. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med 2001;193(6):727–40.

    PubMed  CAS  Google Scholar 

  59. Bemis LT, Schedin P. Reproductive state of rat mammary gland stroma modulates human breast cancer cell migration and invasion. Cancer Res 2000;60(13):3414–8.

    PubMed  CAS  Google Scholar 

  60. Schedin P. Pregnancy-associated breast cancer and metastasis. Nat Rev Cancer 2006;6(4):281–91.

    PubMed  CAS  Google Scholar 

  61. Werb Z, Tremble PM, Behrendtsen O, Crowley E, Damsky CH. Signal transduction through the fibronectin receptor induces collagenase and stromelysin gene expression. J Cell Biol 1989;109(2):877–89.

    PubMed  CAS  Google Scholar 

  62. Rudolph MC, McManaman JL, Hunter L, Phang T, Neville MC. Functional development of the mammary gland: use of expression profiling and trajectory clustering to reveal changes in gene expression during pregnancy, lactation, and involution. J Mammary Gland Biol Neoplasia 2003;8(3):287–307.

    PubMed  Google Scholar 

  63. Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003;19(2):185–93.

    PubMed  CAS  Google Scholar 

  64. Parrish RS, Spencer HJ, 3rd. Effect of normalization on significance testing for oligonucleotide microarrays. J Biopharm Stat 2004;14(3):575–89.

    PubMed  Google Scholar 

  65. Desmouliere A, Chaponnier C, Gabbiani G. Tissue repair, contraction, and the myofibroblast. Wound Repair Regen 2005;13(1):7–12.

    PubMed  Google Scholar 

  66. Leask A, Abraham DJ. TGF-beta signaling and the fibrotic response. FASEB J 2004;18(7):816–27.

    PubMed  CAS  Google Scholar 

  67. Myllyharju J, Kivirikko KI. Collagens, modifying enzymes and their mutations in humans, flies and worms. Trends Genet 2004;20(1):33–43.

    PubMed  CAS  Google Scholar 

  68. Ramaswamy S, Ross KN, Lander ES, Golub TR. A molecular signature of metastasis in primary solid tumors. Nat Genet 2003;33(1):49–54.

    PubMed  CAS  Google Scholar 

  69. Sivridis E, Giatromanolaki A, Koukourakis MI. “Stromatogenesis” and tumor progression. Int J Surg Pathol 2004;12(1):1–9.

    PubMed  Google Scholar 

  70. Selvey S, Haupt LM, Thompson EW, Matthaei KI, Irving MG, Griffiths LR. Stimulation of MMP-11 (stromelysin-3) expression in mouse fibroblasts by cytokines, collagen and co-culture with human breast cancer cell lines. BMC Cancer 2004;4:40.

    PubMed  Google Scholar 

  71. Guo YP, Martin LJ, Hanna W, Banerjee D, Miller N, Fishell E, et al. Growth factors and stromal matrix proteins associated with mammographic densities. Cancer Epidemiol Biomark Prev 2001;10(3):243–8.

    CAS  Google Scholar 

  72. Jimenez-Mallebrera C, Maioli MA, Kim J, Brown SC, Feng L, Lampe AK, et al. A comparative analysis of collagen VI production in muscle, skin and fibroblasts from 14 Ullrich congenital muscular dystrophy patients with dominant and recessive COL6A mutations. Neuromuscul Disord 2006;16(9–10):571–82.

    PubMed  CAS  Google Scholar 

  73. Lampe AK, Bushby KM. Collagen VI related muscle disorders.J Med Genet 2005;42(9):673–85.

    PubMed  CAS  Google Scholar 

  74. Iyengar P, Espina V, Williams TW, Lin Y, Berry D, Jelicks LA,et al. Adipocyte-derived collagen VI affects early mammary tumor progression in vivo, demonstrating a critical interaction in the tumor/stroma microenvironment. J Clin Invest 2005;115(5):1163–76.

    PubMed  CAS  Google Scholar 

  75. Olsen BR. Collagen IX. Int J Biochem Cell Biol 1997;29(4):555–8.

    Google Scholar 

  76. Curino AC, Engelholm LH, Yamada SS, Holmbeck K, Lund LR, Molinolo AA, et al. Intracellular collagen degradation mediated by uPARAP/Endo180 is a major pathway of extracellular matrix turnover during malignancy. J Cell Biol 2005;169(6):977–85.

    PubMed  CAS  Google Scholar 

  77. Engelholm LH, List K, Netzel-Arnett S, Cukierman E, Mitola DJ, Aaronson H, et al. uPARAP/Endo180 is essential for cellular uptake of collagen and promotes fibroblast collagen adhesion. J Cell Biol 2003;160(7):1009–15.

    PubMed  CAS  Google Scholar 

  78. Zijlstra A, Aimes RT, Zhu D, Regazzoni K, Kupriyanova T, Seandel M, et al. Collagenolysis-dependent angiogenesis mediated by matrix metalloproteinase-13 (collagenase-3). J Biol Chem 2004;279(26):27633–45.

    PubMed  CAS  Google Scholar 

  79. Xu J, Rodriguez D, Petitclerc E, Kim JJ, Hangai M, Moon YS, et al. Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo. J Cell Biol 2001;154(5):1069–79.

    PubMed  CAS  Google Scholar 

  80. Roth JM, Caunt M, Cretu A, Akalu A, Policarpio D, Li X, et al. Inhibition of experimental metastasis by targeting the HUIV26 cryptic epitope in collagen. Am J Pathol 2006;168(5):1576–86.

    PubMed  CAS  Google Scholar 

  81. O’Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88(2):277–85.

    PubMed  CAS  Google Scholar 

  82. McEwan PA, Scott PG, Bishop PN, Bella J. Structural correlations in the family of small leucine-rich repeat proteins and proteoglycans. J Struct Biol 2006;155(2):294–305.

    PubMed  CAS  Google Scholar 

  83. Li Y, Aoki T, Mori Y, Ahmad M, Miyamori H, Takino T, et al. Cleavage of lumican by membrane-type matrix metalloproteinase-1 abrogates this proteoglycan-mediated suppression of tumor cell colony formation in soft agar. Cancer Res 2004;64(19):7058–64.

    PubMed  CAS  Google Scholar 

  84. Zhu JX, Goldoni S, Bix G, Owens RT, McQuillan DJ, Reed CC, et al. Decorin evokes protracted internalization and degradation of the epidermal growth factor receptor via caveolar endocytosis. J Biol Chem 2005;280(37):32468–79.

    PubMed  CAS  Google Scholar 

  85. Reed CC, Waterhouse A, Kirby S, Kay P, Owens RT, McQuillan DJ, et al. Decorin prevents metastatic spreading of breast cancer. Oncogene 2005;24(6):1104–10.

    PubMed  CAS  Google Scholar 

  86. Ramirez F, Sakai LY, Dietz HC, Rifkin DB. Fibrillin microfibrils: multipurpose extracellular networks in organismal physiology. Physiol Genomics 2004;19(2):151–4.

    PubMed  CAS  Google Scholar 

  87. Krishnan R, Cleary EG. Elastin gene expression in elastotic human breast cancers and epithelial cell lines. Cancer Res 1990;50(7):2164–71.

    PubMed  CAS  Google Scholar 

  88. Kadar A, Tokes AM, Kulka J, Robert L. Extracellular matrix components in breast carcinomas. Semin Cancer Biol 2002;12(3):243–57.

    PubMed  CAS  Google Scholar 

  89. Isogai Z, Ono RN, Ushiro S, Keene DR, Chen Y, Mazzieri R, et al. Latent transforming growth factor beta-binding protein 1 interacts with fibrillin and is a microfibril-associated protein. J Biol Chem 2003;278 (4):2750–7.

    PubMed  CAS  Google Scholar 

  90. Muraoka RS, Dumont N, Ritter CA, Dugger TC, Brantley DM, Chen J, et al. Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases. J Clin Invest 2002;109(12):1551–9.

    PubMed  CAS  Google Scholar 

  91. Dumont N, Arteaga CL. Transforming growth factor-beta and breast cancer: Tumor promoting effects of transforming growth factor-beta. Breast Cancer Res 2000;2(2):125–32.

    PubMed  CAS  Google Scholar 

  92. McEarchern JA, Kobie JJ, Mack V, Wu RS, Meade-Tollin L, Arteaga CL, et al. Invasion and metastasis of a mammary tumor involves TGF-beta signaling. International journal of cancer 2001;91(1):76–82.

    PubMed  CAS  Google Scholar 

  93. McDaniel SM, Rumer, KK, Biroc, SL, Metz RP, Singh, M, Porter W, et al. Remodeling of the Mammary Microenvironment after Lactation Promotes Breast Tumor Cell Metastasis. Am J Pathol 2006;168(2).

  94. Paszek MJ, Zahir N, Johnson KR, Lakins JN, Rozenberg GI, Gefen A, et al. Tensional homeostasis and the malignant phenotype. Cancer Cell 2005;8(3):241–54.

    PubMed  CAS  Google Scholar 

  95. Aggeler J, Park CS, Bissell MJ. Regulation of milk protein and basement membrane gene expression: the influence of the extracellular matrix. J Dairy Sci 1988;71(10):2830–42.

    Article  PubMed  CAS  Google Scholar 

  96. Myers CA, Schmidhauser C, Mellentin-Michelotti J, Fragoso G, Roskelley CD, Casperson G, et al. Characterization of BCE-1, a transcriptional enhancer regulated by prolactin and extracellular matrix and modulated by the state of histone acetylation. Mol Cell Biol 1998;18(4):2184–95.

    PubMed  CAS  Google Scholar 

  97. Davis GE, Bayless KJ, Davis MJ, Meininger GA. Regulation of tissue injury responses by the exposure of matricryptic sites within extracellular matrix molecules. Am J Pathol 2000;156(5):1489–98.

    PubMed  CAS  Google Scholar 

  98. Labat-Robert J. Cell-matrix interactions in aging: role of receptors and matricryptins. Ageing Res Rev 2004;3(2):233–47.

    PubMed  CAS  Google Scholar 

  99. Giannelli G, Falk-Marzillier J, Schiraldi O, Stetler-Stevenson WG, Quaranta V. Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. Science 1997;277(5323):225–8.

    PubMed  CAS  Google Scholar 

  100. Schenk S, Quaranta V. Tales from the crypt[ic] sites of the extracellular matrix. Trends Cell Biol 2003;13(7):366–75.

    PubMed  CAS  Google Scholar 

  101. Maeda S, Dean DD, Gomez R, Schwartz Z, Boyan BD. The first stage of transforming growth factor beta1 activation is release of the large latent complex from the extracellular matrix of growth plate chondrocytes by matrix vesicle stromelysin-1 (MMP-3). Calcif Tissue Int 2002;70(1):54–65.

    PubMed  CAS  Google Scholar 

  102. Imai K, Hiramatsu A, Fukushima D, Pierschbacher MD, Okada Y. Degradation of decorin by matrix metalloproteinases: identification of the cleavage sites, kinetic analyses and transforming growth factor-beta1 release. Biochem J 1997;322(Pt 3):809–14.

    PubMed  CAS  Google Scholar 

  103. Harris H. Is collagen XV a tumor suppressor? DNA Cell Biol 2003;22(4):225–6.

    PubMed  CAS  Google Scholar 

  104. Vaisanen T, Vaisanen MR, Autio-Harmainen H, Pihlajaniemi T. Type XIII collagen expression is induced during malignant transformation in various epithelial and mesenchymal tumours. J Pathol 2005;207(3):324–35.

    PubMed  CAS  Google Scholar 

  105. Werb Z, Ashkenas J, MacAuley A, Wiesen JF. Extracellular matrix remodeling as a regulator of stromal-epithelial interactions during mammary gland development, involution and carcinogenesis. Braz J Med Biol Res (Revista Brasileira de pesquisas medicas e biologicas/Sociedade Brasileira de Biofisica et al.) 1996;29(9):1087–97.

  106. Liu PC, Liu X, Li Y, Covington M, Wynn R, Huber R, et al. Identification of ADAM10 as a major source of HER2 ectodomain sheddase activity in HER2 overexpressing breast cancer cells. Cancer Biol Ther 2006;5(6):657–64.

    Article  PubMed  CAS  Google Scholar 

  107. Wolfsberg TG, Primakoff P, Myles DG, White JM. ADAM, a novel family of membrane proteins containing A Disintegrin And Metalloprotease domain: multipotential functions in cell–cell and cell–matrix interactions. J Cell Biol 1995;131(2):275–8.

    PubMed  CAS  Google Scholar 

  108. O’Shea C, McKie N, Buggy Y, Duggan C, Hill AD, McDermott E, et al. Expression of ADAM-9 mRNA and protein in human breast cancer. Int J Cancer 2003;105(6):754–61.

    PubMed  CAS  Google Scholar 

  109. Isler SG, Ludwig CU, Chiquet-Ehrismann R, Schenk S. Evidence for transcriptional repression of SPARC-like 1, a gene downregulated in human lung tumors. Int J Oncol 2004;25(4):1073–9.

    PubMed  CAS  Google Scholar 

  110. Tetu B, Brisson J, Wang CS, Lapointe H, Beaudry G, Blanchette C, et al. The influence of MMP-14, TIMP-2 and MMP-2 expression on breast cancer prognosis. Breast Cancer Res 2006;8(3):R28.

    PubMed  Google Scholar 

  111. Sargiannidou I, Zhou J, Tuszynski GP. The role of thrombospondin-1 in tumor progression. Experimental biology and medicine (Maywood, NJ 2001;226(8):726–33.

    CAS  Google Scholar 

  112. Watkins G, Douglas-Jones A, Bryce R, Mansel RE, Jiang WG. Increased levels of SPARC (osteonectin) in human breast cancer tissues and its association with clinical outcomes. Prostaglandins, Leukot Essent Fat Acids 2005;72(4):267–72.

    CAS  Google Scholar 

  113. Shao R, Bao S, Bai X, Blanchette C, Anderson RM, Dang T, et al. Acquired expression of periostin by human breast cancers promotes tumor angiogenesis through up-regulation of vascular endothelial growth factor receptor 2 expression. Mol Cell Biol 2004;24(9):3992–4003.

    PubMed  CAS  Google Scholar 

  114. Anliker B, Muller U. The functions of mammalian amyloid precursor protein and related amyloid precursor-like proteins. Neurodegen Dis 2006;3(4–5):239–46.

    CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by the National Cancer Institute R01 CA85944, the Department of Defense BC051532 and a grant from the Butcher Family Foundation to P.S.

Author information

Authors and Affiliations

  1. AMC Cancer Research Center, University of Colorado Health Science Center, Aurora, CO, USA

    Pepper Schedin

  2. Department of Medicine, Division of Medical Oncology, University of Colorado Health Science Center, Mail Stop 8117, P. O. Box 6511, Aurora, CO, 80045, USA

    Pepper Schedin, Jenean O’Brien & Virginia Borges

  3. Department of Obstetrics and Gynecology, Division of Reproductive Sciences, University of Colorado Health Science Center, Aurora, CO, USA

    Pepper Schedin & Michael Rudolph

  4. Department of Cell and Developmental Biology, University of Colorado Health Science Center, Aurora, CO, USA

    Pepper Schedin

  5. Division of Cancer Sciences and Molecular Pathology, Western Infirmary, University of Glasgow, Glasgow, UK

    Torsten Stein

  6. University of Colorado Cancer Center, University of Colorado Health Science Center, Aurora, CO, USA

    Virginia Borges

Authors
  1. Pepper Schedin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jenean O’Brien
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael Rudolph
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Torsten Stein
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Virginia Borges
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pepper Schedin.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schedin, P., O’Brien, J., Rudolph, M. et al. Microenvironment of the Involuting Mammary Gland Mediates Mammary Cancer Progression. J Mammary Gland Biol Neoplasia 12, 71–82 (2007). https://doi.org/10.1007/s10911-007-9039-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10911-007-9039-3

Keywords

Search

Navigation